Johnson & Johnson

NYSE:JNJ   3:59:58 PM EDT
164.13
+0.41 (+0.25%)
Products

Johnson & Johnson Announces Submission Of Emergency Use Authorization Amendment To The U.S. FDA To Support Booster Of Its Single-Shot COVID-19 Vaccine

Published: 10/05/2021 10:41 GMT
Johnson & Johnson (JNJ) - Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of Its Single-shot Covid-19 Vaccine.
J&j - Company's Single-shot Vaccine Has Demonstrated Strong and Long-lasting Protection and Durable Immune Responses in Clinical Studies.
J&j - Substantial Increase in Immune Response When Booster Was Given at Six Months.
J&j - Submission Includes Data Showing a Booster Increased Protection to 94 Percent Against Moderate to Severe/critical Covid-19 in U.S.j&j - Data Consistent With Phase 3 Ensemble Trial, Where Strong Protection Against Severe/critical Disease.
J&j - Co Plans to Submit Data to Other Regulators, World Health Organization (who) & National Immunization Technical Advisory Groups Worldwide.
J&j - Vaccine, When Given As a Booster Or Primary Dose, Was Generally Well-tolerated.
J&j - No Evidence of Reduced Effectiveness Over Study Duration From March to July 31, 2021.